中文 English
Home
Patient Center
Clinical Trial
About Us
Chairman’s Message Our Company Leadership
Research&Development
Areas of Focus Pipeline
Newsroom
Company News Guidelines&Recomandations Publications
Contact Us
Contacts
Company News
Company News Guidelines&Recomandations Publications
26
2024-09
Gensciences receives FDA Orphan Drug Designation for FRSW117, once-a-week ultra-long-acting recombinant coagulation FVIII Drugs
Gensciences received FDA orphan drug designation for its next-generation ultra-long-acting recombina
17
2024-06
Gensciences will Expose Its Data at ISTH 2024
Gensciences will present new data on its hemophilia therapeutic R&D pipeline at ISTH 2024
25
2023-12
Gensciences Inc. Initiated Phase III Clinical Trial for Its Ultra-Long-Acting Recombinant Coagulation Factor VIII with Once-Weekly Dosing Regimen!
The recombinant human coagulation factor VIII-Fc fusion protein for injection (FRSW117), a new gener
13
2023-12
Pharmacokinetics, Safety and Preliminary Efficacy of Multiple Doses of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) in Previously Treated Adult and Adolescent Subjects with Severe Hemophilia a: Results from an Open-Label
25
2023-10
Investigator Meeting for the Pediatric Phase III Clinical Trial of the First Domestic Long-Acting Recombinant Coagulation Factor VIII Product (FRSW107) Successfully Held in Quanzhou, Fujian
On September 21, 2023, the investigator meeting for the project "AnOpen-label...
13
2023-10
Gensciences: First Subject Enrolled in Phase Ib/II Clinical Trial of the First Domestic Long-Acting Recombinant Activated Factor VII Product (SS109)
Recombinant human coagulation factor FⅦa-Fc fusion protein for injection (SS109) developed
03
2023-07
Great achievements! The First Domestic Long-Acting Recombinant Factor IX Product of Gensciences Approved for Clinical Trial
On July 3, 2023, the Class I innovative drug "Recombinant human coagulation factor IX-Fc fusion prot
27
2023-06
Clinical Data of the Heavyweight Innovative Drug Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (SS327) Developed by Gensciences Presented at 2023 ISTH
The 31st Annual Meeting of the International Society on Thrombosis and Haemostasis (ISTH) 2023
Address
Jiangsu Gensciences：South of Xinxing Road, West of Guangxian Road, Nantong Economic Technolog Development Zone, Jiangsu
Beijing Gensciences：Building 18, Area B, BUT Software Park, 1 Disheng North Street, Daxing District, Beijing
Zhengzhou Gensciences：Building 20, Zhengzhou Linkong Biomedical Park, Zhengzhou Airport Economy District, Henan
Shanghai Gensciences：Building 5, Lane 111, Liangyao Road, Xinchang Township, Pudong New Area, Shanghai
Gensciences Xieyou：Building 5, Lane 111, Liangyao Road, Xinchang Township, Pudong New Area, Shanghai
Links
Home
Patient Center
About Us
Research&Development
Newsroom
Contact Us
WeChat Public Account

Scan to Add

Copyright: Jiangsu Gensciences Inc.     苏ICP备2022048559号-2    ghs苏公网安备32060002000102号